戊柔比星
中文名称 | 戊柔比星 |
---|---|
中文同义词 | 戊柔比星;戊柔吡星;戊柔比星(比星类);戊柔比星 USP标准品;戊柔比星(R&D);缬柔比星;2-氧代-2-((2S,4S)-2,5,12-三羟基-4-(((2R,4S,5S,6S)-5-羟基-6-甲基-4-(2,2,2-三氟乙酰氨基)四氢-2H-吡喃-2-基)氧基)-7-甲氧基-6,11-二氧代-1,2,3,4,6,11-六氢并四苯-2-基)乙基 戊酸酯;戊酸2-氧代-2-((2S,4S)-2,5,12-三羟基-4-(((2R,4S,5S,6S)-5-羟基-6-甲基-4-(2,2,2-三氟乙酰氨基)四氢-2H-吡喃-2-基)氧基)-7-甲氧基-6,11-二氧代-1,2,3,4,6,11-六氢并四苯-2-基)乙酯 |
英文名称 | Valrubicin |
英文同义词 | ad32;antibioticad32;nsc-246131;n-trifluoroacetyladriamycin-14-valerate;n-trifluoroacetyladriamycin14-valerate;n-trifluoroacetyldoxorubicin14-valerate;trifluoroacetyl-adriamyci14-valerate;trifluoroacetyladriamycin-14-valerate |
CAS号 | 56124-62-0 |
分子式 | C34H36F3NO13 |
分子量 | 723.64 |
EINECS号 | 680-664-1 |
相关类别 | BICINS比星类产品(Anti-cancer);医药原料药;医药中间体;原料药【仅供科研】;科研原药系列;医药原料;抗肿瘤;原料;抗癌药;化学试剂;Antineoplastic;Intermediates & Fine Chemicals;Pharmaceuticals;API;医用原料 |
Mol文件 | 56124-62-0.mol |
结构式 |
戊柔比星 性质
熔点 | 116-117 °C |
---|---|
沸点 | 135-136 C |
密度 | 1.3473 (estimate) |
储存条件 | 2-8°C |
溶解度 | 可溶于DMSO(少许)、甲醇(少许) |
形态 | 固体 |
酸度系数(pKa) | 7.34±0.60(Predicted) |
颜色 | 红色 |
水溶解性 | insoluble |
InChIKey | ZOCKGBMQLCSHFP-XGMQQLFPNA-N |
SMILES | C12=C(O)C3=C(C(=O)C4C=CC=C(OC)C=4C3=O)C(O)=C1C[C@@](O)(C(=O)COC(=O)CCCC)C[C@@H]2O[C@@H]1O[C@H]([C@@H](O)[C@@H](NC(=O)C(F)(F)F)C1)C |&1:21,34,36,38,39,41,r| |
Target | Value |
TPA-activated PKC
(Cell-free assay) | 0.85 μM |
PDBu-activated PKC
(Cell-free assay) | 1.25 μM |
Valrubicin (AD 32) is a chemotherapy agent, inhibits TPA- and PDBu-induced PKC activation with IC 50 s of 0.85 and 1.25 μM, respectively. Valrubicin inhibits the binding of [ 3 H]PDBu to PKC. Therefore, Valrubicin competes with the tumor promoter for the PKC binding site and prevents the latter from both interacting with the phospholipid and binding to PKC. Valrubicin shows cytotoxic activity against squamous cell carcinoma (SCC) cell line colony formation, with IC 50 s and IC 90 s of 8.24 ± 1.60 μM and 14.81 ± 2.82 μM for UMSCC5 cells, 15.90 ± 0.90 μM, 29.84 ± 0.84 μM for UMSCC5/CDDP‡ cells, and 10.50 ± 2.39 μM, 19.00 ± 3.91 μM for UMSCC10b cells, respectively. Moreover, Valrubicin in combination with radiation enhances the cytotoxicity.
Valrubicin (3, 6, or 9 mg) reduces tumor growth at week 3 by intratumoral jection in hamster. Valrubicin (6 mg) combined with minimally cytotoxic irradiation (150, 250, or 350 cGy) causes significant tumor shrinkage in hamster. Valrubicin (0.1 μg/μL) significantly reduces the number of infiltrating neutrophils in biopsies challenged with TPA at 24 h and attenuates chronic inflammation in mice. Valrubicin also decreases the expression levels of inflammatory cytokines in the acute model.
安全信息
危险品标志 | Xi |
---|---|
危险类别码 | 36/37/38 |
安全说明 | 26-37/39 |
海关编码 | 2941906000 |
毒害物质数据 | 56124-62-0(Hazardous Substances Data) |
毒性 | dnd-hmn:lym 3 mg/L CJBIAE 58,720,80 |
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | HY-13772 | Valrubicin | 5 mg | 1100元 | |
2024/08/19 | HY-13772 | 戊柔比星 Valrubicin | 56124-62-0 | 10mM * 1mLin DMSO | 1751元 |